Thierry Christophe
Galapagos (Belgium)(BE)
Publications by Year
Research Areas
Tuberculosis Research and Epidemiology, Cancer therapeutics and mechanisms, Osteoarthritis Treatment and Mechanisms, Mycobacterium research and diagnosis, Immune Response and Inflammation
Most-Cited Works
- → Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis(2009)724 cited
- → Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis(2013)600 cited
- → High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors(2009)324 cited
- → Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases(2013)229 cited
- → The Synthetic Peptide Trp-Lys-Tyr-Met-Val-Met-NH2 Specifically Activates Neutrophils through FPRL1/Lipoxin A4 Receptors and Is an Agonist for the Orphan Monocyte-expressed Chemoattractant Receptor FPRL2(2001)205 cited
- → High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling(2010)190 cited
- → Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways(2014)178 cited
- → Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds(2010)167 cited
- → Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis(2017)137 cited
- → The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A4 receptor(2000)124 cited